Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therapy Areas

Cardiovascular

Set Alert for Cardiovascular

Latest From Cardiovascular

Silence Therapeutics Continues Transformation, Improves US Visibility

The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.


Financing Gene Therapy

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.

Clinical Trials Coronavirus COVID-19

Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms

The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.

Cardiovascular Deals

Heart Failure A Key Future Market For Jardiance?

Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) reduces cardiovascular deaths and hospitalizations in certain heart failure patients regardless of whether they have diabetes, and regulatory submissions are expected for the additional indication later this year.

Cardiovascular Clinical Trials

MyoKardia's Mavacamten 'Impressive' In Hypertrophic Cardiomyopathy

MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.

Cardiovascular Clinical Trials

As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran

Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.

Commercial Clinical Trials
See All

CNS

Set Alert for CNS

Latest From Neurology

Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail

Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.

Neurology Clinical Trials

Indivior Reorganizing And Re-Investing In US Commercial Functions

Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.

Advertising, Marketing & Sales Business Strategies

Intrathecal Zolgensma Delay Could Allow Competitors To Shine

The rollercoaster ride continues for Novartis’s gene therapy Zolgensma, with the company committing to providing further clinical data on an intrathecal formulation for older spinal muscular atrophy patients.

Clinical Trials Gene Therapy

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Clinical Trials Business Strategies

Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone

Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.

Clinical Trials Neurology

BI Finds Right Fit For Digital Therapeutic Partnership With Click

Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m. 

Digital Health Deals
See All

Immunology

Set Alert for Immunology

Latest From Immune Disorders

Sun’s Ilumya To Claw Into Japanese Psoriasis Market

Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.

Immune Disorders Launches

Merck KGaA Rebounds After COVID-19 Lockdowns

The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.

Sales & Earnings Business Strategies

Ziritaxestat Phase II Success Gives Galapagos Something To Cheer

It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.

Clinical Trials Companies

Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late

The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.

Immune Disorders Clinical Trials

Corbus Seeking Way Forward In Systemic Sclerosis After Phase III

The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations. 

Clinical Trials Immune Disorders

Stockwatch: Winlevi And Aimmune Excitement Will Be Short-Lived

Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.

Stockwatch M & A
See All

Infectious

Set Alert for Infectious Diseases

Latest From Infectious Diseases

Coronavirus Update: Novavax Launches Phase III Trial In UK As Virus Surges Back

Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

Coronavirus COVID-19 Companies

'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.

Policy & Regulation Coronavirus COVID-19

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.

Clinical Trials Manufacturing

Coronavirus Update: BioNTech Gets €375m From Germany To Fund Vaccine

Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.

Clinical Trials Companies

Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day

Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial. 

Coronavirus COVID-19 Clinical Trials
See All

Metabolic

Set Alert for Metabolic

Latest From Metabolic Disorders

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.

Clinical Trials Coronavirus COVID-19

Korea Gains Speed In Race For NASH Therapies

NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.

South Korea Research and Development Strategies

Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus

Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.

Biosimilars Metabolic Disorders

DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front

A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.

Clinical Trials Companies

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Deals Commercial

Novo Nordisk, Evotec Link Around Chronic Kidney Disease

Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.

Deals Commercial
See All

Oncology

Set Alert for Oncology

Latest From Cancer

Tech Transfer Roundup: Oncology Deals Focus On CAR-T Innovations, ADCs, DNA Damage Response

Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.

Deals Research and Development Strategies

Monte Rosa Hits The Heights With $96m Cash Hike

The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.

Financing Cancer

ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise

TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.

Commercial Clinical Trials

China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World

The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.

Research & Development Cancer

ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC

Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.

Clinical Trials Companies

Janssen’s Amivantamab Combo Shows Promise In First-Line NSCLC

Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator. 

Clinical Trials Research & Development
See All

Respiratory

Set Alert for Respiratory

Latest From Respiratory

Ziritaxestat Phase II Success Gives Galapagos Something To Cheer

It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.

Clinical Trials Companies

GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US

Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.

Respiratory Approvals

Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19

The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip.

Coronavirus COVID-19 Deals

Merck & Co's Gefapixant Effective In Refractory Cough, But Taste Concerns Remain

Updated results from two Merck & Co Phase III studies, COUGH-1 and COUGH-2, confirm the drug’s efficacy in reducing the frequency of refractory cough and its association with taste disturbances.

Clinical Trials Respiratory

Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma

While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.

Respiratory Clinical Trials

Santhera Doubles Its DMD Portfolio By Taking Option On Vamorolone

Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.

Deals Business Strategies
See All
UsernamePublicRestriction

Register